Gene clues may unlock new treatments for bone marrow cancer

NCT ID NCT06559033

Recruiting now Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether changes in the GBA and PSAP genes are more common in people with multiple myeloma or its precursor condition, MGUS. Researchers will compare the frequency of these gene variants in 300 patients against known population databases. The goal is to better understand the biology of these diseases and potentially identify new treatment approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If certain gene variants are more common in these patients, it could point toward new treatment targets for multiple myeloma and MGUS.
What could go wrong: This is an observational study that only looks for genetic patterns, not a treatment trial. It may not lead to any direct benefit for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE MYELOMA MULTIPLE

Contacts and locations

Locations

Centre Henri Becquerel
NOT_YET_RECRUITING

Rouen, 76000, France
University Rouen Hospital
RECRUITING

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.